Listed companies actively layout the field of covid-19 virus antigen detection Beijing Strong Biotechnologies Inc(300406) 4 on April 19, the company said on the interactive platform that it was accelerating the registration of covid-19 virus antigen detection kit in China Hybio Pharmaceutical Co.Ltd(300199) 418 announcement, the company intends to cooperate in the research and development of household New Coronavirus antigen detection kit.
Industry insiders believe that the great increase in the demand for covid-19 virus antigen detection in China will drive the industrial chain to a market space of 100 billion yuan. At the same time, Chinese enterprises have emerged in the overseas market, and the product power and channels have been verified. The demand for covid-19 virus antigen self-test in the overseas market is about several times that in China, and the market scale is further expanded. It is suggested to continue to pay attention to the upstream and downstream opportunities of the industrial chain.
listed companies actively layout
Recently, the State Council has formulated the “COVID-19 virus antigen detection application plan” (Trial Implementation) to the comprehensive group of New Coronavirus pneumonia epidemic prevention and control mechanism, and has included antigen detection in the prevention and treatment of COVID-19 pneumonia. As of April 13, the State Food and drug administration has approved 27 covid-19 virus antigen detection reagent products.
In terms of listed companies, Beijing Strong Biotechnologies Inc(300406) said that New Coronavirus’s (2019-nCOV) antigen detection kit (latex method) product has obtained EU CE access qualification, and the company is accelerating the registration of COVID-19 virus detection kit in China.
In terms of overseas market layout, Hangzhou Biotest Biotech Co.Ltd(688767) april 19 announced that the covid-19 virus antigen self-test reagent of the company has recently obtained the registration certificate or production and sales license of medical devices in Brazil and Myanmar.
The sharp increase in market demand boosted the performance of relevant listed companies Andon Health Co.Ltd(002432) recently announced that the net profit in the first quarter is expected to be 14-16 billion yuan, a year-on-year increase of 367 to 420 times. Affected by the epidemic, the demand for covid-19 virus antigen detection kit products in the United States has increased significantly, and the growth of sales revenue of this product has made an important contribution to the company’s performance during the reporting period.
Wuhan Easy Diagnosis Biomedicine Co.Ltd(002932) it is estimated that the net profit in the first quarter is 1.35-1.45 billion yuan, with a year-on-year increase of 295.61% – 324.91%. Since January 2022, the company’s export orders of nucleic acid detection reagents and antigen detection kits have increased significantly year-on-year. Covid-19 virus antigen detection kit of the company has won the bid in many provinces across the country.
Because the company’s New Coronavirus antigen detection kit (colloidal gold) related products are sold in Europe, Japan and other markets, Shenzhen Yhlo Biotech Co.Ltd(688575) expects net profit in the first quarter of this year to be 450 million yuan -5 billion yuan, an increase of 109475%-1227.5% over the same period last year.
industrial chain related companies attracted attention
In April 7th, Qinghai issued the notice on the announcement of information about the public New Coronavirus antigen detection kit, and the price tag in Shandong’s Boko diagnostics was 5 yuan / person, which refreshed the lowest price of the hanging network in the provinces where the antigenic reagent had been published.
Citic Securities Company Limited(600030) believes that the short-term demand for antigen detection in China is dominated by the mandatory demand in the sealed area. In the long run, the demand for self medication guidance may be released intensively, superimposed on the normal demand, and the market scale is expected to reach 12 billion yuan / month. According to the cost splitting data in Zhejiang Orient Gene Biotech Co.Ltd(688298) prospectus, it is estimated that the market demand for upstream antigen antibody, NC film, sampling swab and pipette, plastic cartridge, test paper and packaging ex factory caliber in China’s antigen detection market accounts for 4.3%, 2.9%, 2.9%, 1.4% and 6.6% respectively. At the same time, upstream enterprises can share the global market. In addition, in addition to providing performance increment by itself, antigen detection reagents may have greater significance in draining channels such as pharmacies and driving the sales of other products.
Companies related to the industrial chain have attracted much attention Zhejiangtailin Bioengineering Co.Ltd(300813) 419 said on the interactive platform that at present, the customers who buy the company’s NC membrane are mainly in the field of covid-19 virus antigen detection, as well as other detection companies. The company’s NC film began small batch production in March, but the current production capacity is small.
